Skip to content
Buy This GLP
← Research
Formats

Why TERN-601 Development Stopped After a Liver Safety Signal

The experimental oral GLP-1 produced weight loss in early trials. Its sponsor stopped development after three phase 2 participants had substantial liver enzyme elevations.

Editorial profile: Carla MedinaBuy This GLP Editorial Team4 min read
TERN-601 clinical developmentphase 1 — weight loss vs placebophase 2 — weight loss in higher-dose armsthree transaminase elevationsdevelopment discontinuedThe liver findings led to discontinuation.

TERN-601 was an experimental daily pill for adults with obesity or overweight [1]. Our comparison of GLP-1 pills and injections covers products consumers can buy. TERN-601 never reached approval. Its sponsor ended development after a liver safety signal.

What the trials found

Participants in the 28-day phase 1 trial lost more weight than placebo at each dose tested [1]. In the 12-week phase 2 trial, estimated average weight losses in the four active groups ranged from 2.2 to 5.0 kg. The placebo group lost an estimated 0.5 kg. The largest average loss occurred in a 500 mg group, and the highest dose did not produce the largest loss.

Why the sponsor stopped development

Three phase 2 participants had substantial rises in the liver enzymes ALT or AST [1]. The enzymes peaked several weeks after the last dose. One event was reported as serious drug-induced liver injury. The authors identified the liver findings as the main reason development stopped.

Liver enzyme elevations prompted scrutiny of this particular drug. Studies of GLP-1 drugs for fatty liver disease test different products and measure different outcomes. The TERN-601 trial cannot estimate liver injury risk for other oral GLP-1 medicines.

Frequently asked

Why did TERN-601 development stop?
Three phase 2 participants had substantial liver enzyme elevations. One event was reported as serious drug-induced liver injury.
Did participants lose weight on TERN-601?
At week 12, estimated average weight losses across four active groups ranged from 2.2 to 5.0 kg. The placebo group lost an estimated 0.5 kg.
Do these findings apply to other oral GLP-1s?
The findings concern TERN-601. The trials cannot estimate liver injury risk for a different medicine.

Sources

  1. [1] Garvey WT, et al. (2026). Oral GLP-1RA TERN-601 for Adults With Obesity/Overweight: Placebo-Controlled, Multiple-Ascending-Dose, Phase 1 and 2 Studies Obesity. PMID 42528333

Where to get it

Price the oral sellers

Switch the desk to tablets and it prices the oral product itself, never a figure borrowed from the same seller's injection page.

Open the price desk →

More in Formats